CAMBRIDGE, MA, August 20, 2024 (EZ Newswire) -- AlgoDx, a leading medical AI company with EU and UK-approved ML-based software for sepsis prediction in commercial use, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its sepsis detection software using a proprietary algorithm, NAVOY CDS®. This milestone marks a major step forward in AlgoDx’s expansion into the U.S. market.
NAVOY CDS® is a software as a medical device (SaMD) designed to support clinicians in identifying sepsis in hospitalized patients, including the emergency department. By leveraging routinely collected vital parameters, the software analyzes patient data to provide early warnings of sepsis, a life-threatening condition, enabling healthcare providers to initiate timely interventions.
"Receiving FDA clearance for NAVOY CDS® is a testament to our team’s dedication and expertise in developing cutting-edge medical device software for healthcare," said Andreas Macura, Chief Product Officer at AlgoDx. "We believe that NAVOY CDS® has the potential to significantly improve patient outcomes by enabling earlier detection and treatment of sepsis."
Dr. Enrico Petrillo, Director of International Research and Strategic Initiatives at Brigham and Women’s Hospital, Faculty Lecturer at Harvard Medical School, Executive Director at Network Medicine Alliance and Institute, and board chairman at AlgoDx, added, "This FDA clearance is a pivotal moment for AlgoDx as we expand our presence in the U.S. It validates our commitment to developing innovative technologies that address critical healthcare challenges. We look forward to bringing NAVOY CDS® to health systems nationwide."
Sepsis is the leading cause of in-hospital mortality worldwide, accounting for approximately 35% of all hospital deaths. Sepsis is a life-threatening condition caused by an extreme immune system response to an infection. It is a medical emergency that can lead to organ failure and death. Early detection and treatment are crucial for improving a patient’s chance of surviving sepsis. AlgoDx’s solutions offer the potential to improve sepsis care by providing healthcare providers with a powerful tool to identify patients at risk in the emergency department as well as other hospital wards.
About AlgoDx
AlgoDx is a digital health company that enables physicians and healthcare providers to use data-driven solutions to deliver better patient outcomes and reduce costs. Recognized as one of the best startups in Sweden, AlgoDx is committed to developing innovative decision-support tools for critical care that use artificial intelligence and machine learning to provide insights for predicting acute complications. AlgoDx's main offering, NAVOY®, focuses on sepsis, a medical condition with high mortality rates and significant financial and social impact. For more information, visit https://algodx.com.
Media Contact
David Becedas
About AlgoDx
AlgoDx is a digital health company that enables physicians and healthcare providers to use data-driven solutions to deliver better patient outcomes and reduce costs. Recognized as one of the best startups in Sweden, AlgoDx is committed to developing innovative decision-support tools for critical care that use artificial intelligence and machine learning to provide insights for predicting acute complications. AlgoDx's main offering, NAVOY®, focuses on sepsis, a medical condition with high mortality rates and significant financial and social impact. For more information, visit https://algodx.com.
Media Contact
David Becedas
###
